References
- Circular of Information for the Use of Human Blood and Blood Components. Published by AABB, October 2017. https://www.aabb.org/tm/coi/Documents/coi1017.pdf.
- Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007;23:20–33.
- Fung MK, Downes KA, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med 2007;131: 909–16.
- Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010;42:83–8.
- Karafin MS, Blagg L, Tobian AA, King KE, Ness PM, Savage WJ. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012;52:2087–93.
- Garratty G. Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol 1998;109: 769–77.
- Harris SB, Josephson CD, Kost CB, Hillyer CD. Nonfatal intravascular hemolysis in a pediatric patient after transfusion of a platelet unit with high-titer anti-A. Transfusion 2007; 47:1412–7.
- Balbuena-Merle R, West FB, Tormey CA, Hendrickson JE. Fatal acute hemolytic transfusion reaction due to anti-B from a platelet apheresis unit stored in platelet additive solution. Transfusion 2019;59:1911–5.
- Daniel-Johnson J, Leitman S, Klein H, et al. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009;49:1845–9.
- Fontaine MJ, Webster J, Gomez S, Pham TD, Goodnough LT, Galel SA. How do I implement an automated screen for high-titer ABO antibody as an inventory management tool for ABO plasma-incompatible platelets? Transfusion 2015;55:2783–9.
- Cooling LL, Downs TA, Butch SH, Davenport RD. Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets. Transfusion 2008;48:2106–13.
- Fontaine MJ, Mills AM, Weiss S, Hong WJ, Viele M, Goodnough LT. How we treat: risk mitigation for ABO-incompatible plasma in platelet pheresis products. Transfusion 2012;52:2081–5.